Skip to main content

Advertisement

Table 2 Final model for the stepwise Cox hazard model analysis showing Hazard Ratio (with relative confidence intervals and p-values) for relapsing after the increase of IFNB dose.

From: Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

  HR 95% C.I. p-value
Male gender 0.68 0.39 - 1.16 0.1
Age at switch (each year) 0.94 0.91 - 0.97 <0.001
No. of relapses occurred during the low-dose IFNB regimen    
   0 (*) Ref. - -
   1 3.56 1.34 - 8.42 0.01
   ≥ 2 7.89 3.10 - 19.85 <0.001
IFNB type (Betaferon or Rebif 44) 1.14 0.52 - 2.51 0.7
  1. IFNB: Interferon Beta; EDSS: Expanded Disability Status Scale
  2. (*) this value refers to patients switched only on the basis of an active MRI scan